{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:11:10Z","timestamp":1777363870849,"version":"3.51.4"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01352-y","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:36:28Z","timestamp":1739208988000},"page":"579-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[]},{"given":"Maria J.","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Filipe","sequence":"additional","affiliation":[]},{"given":"Maria J. P.","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"1352_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"1352_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/DER.0000000000000598","volume":"31","author":"S Capucci","year":"2020","unstructured":"Capucci S, Hahn-Pedersen J, Vilsb\u00f8ll A, et al. Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis. 2020;31:178\u201384. https:\/\/doi.org\/10.1097\/DER.0000000000000598.","journal-title":"Dermatitis"},{"key":"1352_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66:8\u201316. https:\/\/doi.org\/10.1159\/000370220.","journal-title":"Ann Nutr Metab"},{"key":"1352_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/pai.13335","volume":"32","author":"NA Suaini","year":"2021","unstructured":"Suaini NA, Tan CPT, Loo EA, et al. Global differences in atopic dermatitis. Pediatr Allergy Immunol. 2021;32:23\u201333. https:\/\/doi.org\/10.1111\/pai.13335.","journal-title":"Pediatr Allergy Immunol"},{"key":"1352_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","volume":"27","author":"BA Kaufman","year":"2018","unstructured":"Kaufman BA, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340\u201357. https:\/\/doi.org\/10.1111\/exd.13514.","journal-title":"Exp Dermatol"},{"key":"1352_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12016-021-08880-3","volume":"61","author":"H Li","year":"2021","unstructured":"Li H, Zhang Z, Zhang H, et al. Update on the pathogenesis and therapy of atopic dermatitis. Clin Rev Allergy Immunol. 2021;61:324\u201338. https:\/\/doi.org\/10.1007\/s12016-021-08880-3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1352_CR7","doi-asserted-by":"publisher","first-page":"adv00162","DOI":"10.2340\/00015555-3512","volume":"100","author":"J Thyssen","year":"2020","unstructured":"Thyssen J, Rinnov M, Vestergaard C. Disease mechanisms in atopic dermatitis: a review of aetiological factors. Acta Dermato Venereol. 2020;100:adv00162. https:\/\/doi.org\/10.2340\/00015555-3512.","journal-title":"Acta Dermato Venereol"},{"key":"1352_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.det.2017.02.006","volume":"35","author":"K Malik","year":"2017","unstructured":"Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017;35:317\u201326. https:\/\/doi.org\/10.1016\/j.det.2017.02.006.","journal-title":"Dermatol Clin"},{"key":"1352_CR9","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13444","volume":"10","author":"SM Nur Husna","year":"2022","unstructured":"Nur Husna SM, Md Shukri N, Mohd Ashari NS, et al. IL-4\/IL-13 axis as therapeutic targets in allergic rhinitis and asthma. PeerJ. 2022;10:e13444. https:\/\/doi.org\/10.7717\/peerj.13444.","journal-title":"PeerJ"},{"key":"1352_CR10","first-page":"107","volume":"23","author":"S Micheal","year":"2013","unstructured":"Micheal S, Minhas K, Ishaque M, et al. IL-4 gene polymorphisms and their association with atopic asthma and allergic rhinitis in Pakistani patients. J Investig Allergol Clin Immunol. 2013;23:107\u201311.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1352_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","volume":"143","author":"AS Paller","year":"2019","unstructured":"Paller AS, Spergel JM, Mina-Osorio P, et al. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143:46\u201355. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.006.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666x.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17:835\u201352. https:\/\/doi.org\/10.1080\/1744666x.2021.1940962.","journal-title":"Expert Rev Clin Immunol"},{"key":"1352_CR13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jid.2021.01.022","volume":"141","author":"DS Bakker","year":"2021","unstructured":"Bakker DS, van der Wal MM, Heeb LEM, et al. Early and long-term effects of dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis. J Investig Dermatol. 2021;141:1523\u2013747. https:\/\/doi.org\/10.1016\/j.jid.2021.01.022.","journal-title":"J Investig Dermatol"},{"key":"1352_CR14","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/biomedicines10112700","volume":"10","author":"G Radi","year":"2022","unstructured":"Radi G, Campanti A, Diotallevi F, et al. A systematic review of atopic dermatitis: the intriguing journey starting from physiopathology to treatment, from laboratory bench to bedside. Biomedicines. 2022;10:2700\u20132700. https:\/\/doi.org\/10.3390\/biomedicines10112700.","journal-title":"Biomedicines"},{"key":"1352_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/cells13050425","volume":"13","author":"A Pareek","year":"2024","unstructured":"Pareek A, Kumari L, Pareek A, et al. Unraveling atopic dermatitis: insights into pathophysiology, therapeutic advances, and future perspectives. Cells. 2024;13:425. https:\/\/doi.org\/10.3390\/cells13050425.","journal-title":"Cells"},{"key":"1352_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40:84\u201392. https:\/\/doi.org\/10.2500\/aap.2019.40.4202.","journal-title":"Allergy Asthma Proc"},{"key":"1352_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/jid.2011.393","volume":"132","author":"SJ Brown","year":"2012","unstructured":"Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Investig Dermatol. 2012;132:751\u201362. https:\/\/doi.org\/10.1038\/jid.2011.393.","journal-title":"J Investig Dermatol"},{"key":"1352_CR18","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMra1011040","volume":"365","author":"AD Irvine","year":"2011","unstructured":"Irvine AD, McLean WH, Leung DYM. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315\u201327. https:\/\/doi.org\/10.1056\/NEJMra1011040.","journal-title":"N Engl J Med"},{"key":"1352_CR19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.2147\/jaa.s293900","volume":"15","author":"AC Chong","year":"2022","unstructured":"Chong AC, Visitsunthorn K, Ong PY. Genetic\/environmental contributions and immune dysregulation in children with atopic dermatitis. J Asthma Allergy. 2022;15:1681\u2013700. https:\/\/doi.org\/10.2147\/jaa.s293900.","journal-title":"J Asthma Allergy"},{"key":"1352_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4168\/aair.2012.4.1.12","volume":"21","author":"BE Kim","year":"2011","unstructured":"Kim BE, Leung DY. Epidermal barrier in atopic dermatitis. Allergy Asthma Immunol. 2011;21:12\u20136. https:\/\/doi.org\/10.4168\/aair.2012.4.1.12.","journal-title":"Allergy Asthma Immunol"},{"key":"1352_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-017-0044-7","author":"P Rerknimitr","year":"2017","unstructured":"Rerknimitr P, Otsuka A, Nakashima C, et al. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regener. 2017. https:\/\/doi.org\/10.1186\/s41232-017-0044-7.","journal-title":"Inflamm Regener"},{"key":"1352_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s40521-015-0056-y","volume":"2","author":"M-L Clausen","year":"2015","unstructured":"Clausen M-L, Agner T, Thomsen SF. Skin barrier dysfunction and the atopic march. Curr Treat Opt Allergy. 2015;2:218\u201327. https:\/\/doi.org\/10.1007\/s40521-015-0056-y.","journal-title":"Curr Treat Opt Allergy"},{"key":"1352_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12016-015-8508-5","volume":"51","author":"Y Liang","year":"2016","unstructured":"Liang Y, Chang C, Lu Q. The genetics and epigenetics of atopic dermatitis\u2014filaggrin and other polymorphisms. Clin Rev Allergy Immunol. 2016;51:315\u201328. https:\/\/doi.org\/10.1007\/s12016-015-8508-5.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1352_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jaci.2016.02.030","volume":"138","author":"M Noval Rivas","year":"2016","unstructured":"Noval Rivas M, Burton OT, Oettgen HC, et al. IL-4 production by group\u00a02 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016;138:801-811.e809. https:\/\/doi.org\/10.1016\/j.jaci.2016.02.030.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR25","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jid.2024.06.1280","volume":"144","author":"J Simmons","year":"2024","unstructured":"Simmons J, Gallo RL. The central roles of keratinocytes in coordinating skin immunity. J Investig Dermatol. 2024;144:2377\u201398. https:\/\/doi.org\/10.1016\/j.jid.2024.06.1280.","journal-title":"J Investig Dermatol"},{"key":"1352_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, et al. Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.012.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000539534","volume":"16","author":"Y Pan","year":"2024","unstructured":"Pan Y, Wang Y, Xu M, et al. The roles of innate immune cells in atopic dermatitis. J Innate Immun. 2024;16:385\u201396. https:\/\/doi.org\/10.1159\/000539534.","journal-title":"J Innate Immun"},{"key":"1352_CR28","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.3390\/jcm12072701","volume":"12","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Maurelli M, Calabrese L, et al. Overview of atopic dermatitis in different ethnic groups. J Clin Med. 2023;12:2701. https:\/\/doi.org\/10.3390\/jcm12072701.","journal-title":"J Clin Med"},{"key":"1352_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","volume":"51","author":"NK Mollanazar","year":"2016","unstructured":"Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51:263\u201392. https:\/\/doi.org\/10.1007\/s12016-015-8488-5.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1352_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-015-0567-4","author":"MR Williams","year":"2015","unstructured":"Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015. https:\/\/doi.org\/10.1007\/s11882-015-0567-4.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1352_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13792","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Fan N, Gu X, et al. Characteristics of gut microbiota and serum metabolism in patients with atopic dermatitis. Skin Res Technol. 2024. https:\/\/doi.org\/10.1111\/srt.13792.","journal-title":"Skin Res Technol"},{"key":"1352_CR32","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/exd.14016","volume":"28","author":"M Sz\u00e1nt\u00f3","year":"2019","unstructured":"Sz\u00e1nt\u00f3 M, D\u00f3zsa A, Antal D, et al. Targeting the gut-skin axis\u2014probiotics as new tools for skin disorder management? Exp Dermatol. 2019;28:1210\u20138. https:\/\/doi.org\/10.1111\/exd.14016.","journal-title":"Exp Dermatol"},{"key":"1352_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/all.16318","author":"N Sun","year":"2024","unstructured":"Sun N, Ogulur I, Mitamura Y, et al. The epithelial barrier theory and its associated diseases. Allergy. 2024. https:\/\/doi.org\/10.1111\/all.16318.","journal-title":"Allergy"},{"key":"1352_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4168\/aair.2018.10.4.354","volume":"10","author":"S-Y Lee","year":"2018","unstructured":"Lee S-Y, Lee E, Park YM, et al. Microbiome in the gut-skin axis in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10:354. https:\/\/doi.org\/10.4168\/aair.2018.10.4.354.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1352_CR35","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/all.16092","volume":"79","author":"RB Canani","year":"2024","unstructured":"Canani RB, Caminati M, Carucci L, et al. Skin, gut, and lung barrier: physiological interface and target of intervention for preventing and treating allergic diseases. Allergy. 2024;79:1485\u2013500. https:\/\/doi.org\/10.1111\/all.16092.","journal-title":"Allergy"},{"key":"1352_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-4899-0987-9_21","volume-title":"Mechanisms of lymphocyte activation and immune regulation V","author":"A Keegan","year":"1994","unstructured":"Keegan A, Nelms K, Paul WE. The IL-4 receptor\u2014signaling mechanisms. In: Mechanisms of lymphocyte activation and immune regulation V. New York: Springer; 1994. p. 211\u20135."},{"key":"1352_CR37","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9:e670\u20137. https:\/\/doi.org\/10.1016\/S2352-3026(22)00165-X.","journal-title":"Lancet Haematol"},{"key":"1352_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/aci.0000000000000553","volume":"19","author":"LM Roesner","year":"2019","unstructured":"Roesner LM, Zeitvogel J, Heratizadeh A. Common and different roles of IL-4 and IL-13 in skin allergy and clinical implications. Curr Opin Allergy Clin Immunol. 2019;19:319\u201327. https:\/\/doi.org\/10.1097\/aci.0000000000000553.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1352_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/critrevimmunol.v17.i1.10","volume":"17","author":"MA Brown","year":"1997","unstructured":"Brown MA, Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol. 1997;17:1\u201332. https:\/\/doi.org\/10.1615\/critrevimmunol.v17.i1.10.","journal-title":"Crit Rev Immunol"},{"key":"1352_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1342176","author":"Y Yamamura","year":"2024","unstructured":"Yamamura Y, Nakashima C, Otsuka A. Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1342176.","journal-title":"Front Med"},{"key":"1352_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/ITT.S260370","volume":"29","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Maurelli M, Peris K, et al. Targeting IL-4 for the treatment of atopic der matitis. Immunotargets Ther. 2020;29:151\u20136. https:\/\/doi.org\/10.2147\/ITT.S260370.","journal-title":"Immunotargets Ther"},{"key":"1352_CR42","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3390\/cells12242793","volume":"12","author":"PR Upadhyay","year":"2023","unstructured":"Upadhyay PR, Seminario-Vidal L, Abe B, et al. Cytokines and epidermal lipid abnormalities in atopic dermatitis: a systematic review. Cells. 2023;12:2793. https:\/\/doi.org\/10.3390\/cells12242793.","journal-title":"Cells"},{"key":"1352_CR43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cyto.2012.10.031","volume":"61","author":"L Bao","year":"2013","unstructured":"Bao L, Shi VY, Chan LS. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. Cytokine. 2013;61:419\u201325. https:\/\/doi.org\/10.1016\/j.cyto.2012.10.031.","journal-title":"Cytokine"},{"key":"1352_CR44","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1038\/jid.2010.161","volume":"130","author":"J Ishikawa","year":"2010","unstructured":"Ishikawa J, Narita H, Kondo N, et al. Changes in the ceramide profile of atopic dermatitis patients. J Investig Dermatol. 2010;130:2511\u20134. https:\/\/doi.org\/10.1038\/jid.2010.161.","journal-title":"J Investig Dermatol"},{"key":"1352_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98006","author":"E Berdyshev","year":"2018","unstructured":"Berdyshev E, Goleva E, Bronova I, et al. Lipid abnormalities in atopic skin are driven by type\u00a02 cytokines. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.98006.","journal-title":"JCI Insight"},{"key":"1352_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdermsci.2017.05.005","volume":"88","author":"M Danso","year":"2017","unstructured":"Danso M, Boiten W, Van Drongelen V, et al. Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci. 2017;88:57\u201366. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.05.005.","journal-title":"J Dermatol Sci"},{"key":"1352_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.31083\/j.fbl2902084","volume":"29","author":"M Savva","year":"2024","unstructured":"Savva M, Papadopoulos NG, Gregoriou S, et al. Recent advancements in the atopic dermatitis mechanism. Front Biosci Landmark. 2024;29:84. https:\/\/doi.org\/10.31083\/j.fbl2902084.","journal-title":"Front Biosci Landmark"},{"key":"1352_CR48","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.jid.2016.05.127","volume":"136","author":"T Nakatsuji","year":"2016","unstructured":"Nakatsuji T, Chen TH, Two AM, et al. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression. J Investig Dermatol. 2016;136:2192\u2013200. https:\/\/doi.org\/10.1016\/j.jid.2016.05.127.","journal-title":"J Investig Dermatol"},{"key":"1352_CR49","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.3390\/ijms20164053","volume":"20","author":"S Miake","year":"2019","unstructured":"Miake S, Tsuji G, Takemura M, et al. IL-4 augments IL-31\/IL-31 receptor alpha interaction leading to enhanced Ccl 17 and Ccl 22 production in dendritic cells: implications for atopic dermatitis. Int J Mol Sci. 2019;20:4053. https:\/\/doi.org\/10.3390\/ijms20164053.","journal-title":"Int J Mol Sci"},{"key":"1352_CR50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171:217-228.e213. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"key":"1352_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108348","volume":"242","author":"Y G\u00e4rtner","year":"2023","unstructured":"G\u00e4rtner Y, Bitar L, Zipp F, et al. Interleukin-4 as a therapeutic target. Pharmacol Ther. 2023;242: 108348. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108348.","journal-title":"Pharmacol Ther"},{"key":"1352_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.iac.2016.08.007","volume":"37","author":"M Kido-Nakahara","year":"2017","unstructured":"Kido-Nakahara M, Furue M, Ulzii D, et al. Itch in atopic dermatitis. Immunol Allergy Clin North Am. 2017;37:113\u201322. https:\/\/doi.org\/10.1016\/j.iac.2016.08.007.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1352_CR53","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1046\/j.0022-202x.2001.01484.x","volume":"117","author":"LS Chan","year":"2001","unstructured":"Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Investig Dermatol. 2001;117:977\u201383. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01484.x.","journal-title":"J Investig Dermatol"},{"key":"1352_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03769-7","author":"J Cui","year":"2021","unstructured":"Cui J, Xu H, Yu J, et al. IL-4 inhibits regulatory T\u00a0cells differentiation by HDAC9-mediated epigenetic regulation. Cell Death Dis. 2021. https:\/\/doi.org\/10.1038\/s41419-021-03769-7.","journal-title":"Cell Death Dis"},{"key":"1352_CR55","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.4049\/jimmunol.177.4.2131","volume":"177","author":"G Iezzi","year":"2006","unstructured":"Iezzi G, Boni A, Degl\u2019Innocenti E, et al. Type\u00a02 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type\u00a02 immune responses. J Immunol. 2006;177:2131\u20137. https:\/\/doi.org\/10.4049\/jimmunol.177.4.2131.","journal-title":"J Immunol"},{"key":"1352_CR56","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/365340a0","volume":"365","author":"J-F Gauchat","year":"1993","unstructured":"Gauchat J-F, Henchoz S, Mazzei G, et al. Induction of human IgE synthesis in B\u00a0cells by mast cells and basophils. Nature. 1993;365:340\u20133. https:\/\/doi.org\/10.1038\/365340a0.","journal-title":"Nature"},{"key":"1352_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/09629359791802","volume":"6","author":"B Niggemann","year":"1997","unstructured":"Niggemann B, Zuberbier T, Herz U, et al. Interleukin-4 (IL-4) enhances and soluble interleukin-4 receptor (sIL-4R) inhibits histamine release from peripheral blood basophils and mast cells in vitro and in vivo. Mediators Inflamm. 1997;6:111\u20138. https:\/\/doi.org\/10.1080\/09629359791802.","journal-title":"Mediators Inflamm"},{"key":"1352_CR58","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.3390\/ijms23126682","volume":"23","author":"R Tanei","year":"2022","unstructured":"Tanei R, Hasegawa Y. Immunological pathomechanisms of spongiotic dermatitis in skin lesions of atopic dermatitis. Int J Mol Sci. 2022;23:6682. https:\/\/doi.org\/10.3390\/ijms23126682.","journal-title":"Int J Mol Sci"},{"key":"1352_CR59","doi-asserted-by":"publisher","first-page":"AB16","DOI":"10.1016\/j.jaci.2023.11.070","volume":"153","author":"B Kim","year":"2024","unstructured":"Kim B, Beck L, Simpson E, et al. Dupilumab reduction of IgE levels and probability of atopic dermatitis flares\u2014analysis of a randomized placebo-controlled 52-week study. J Allergy Clin Immunol. 2024;153:AB16. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.070.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR60","doi-asserted-by":"publisher","unstructured":"Sawada E, Yoshida N, Sugiura A, et al. Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: An implication for the disrupted barrier mechanism in atopic dermatitis. J. Dermatol. Sci. 2012;68:25\u201335. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.07.004.","DOI":"10.1016\/j.jdermsci.2012.07.004"},{"key":"1352_CR61","doi-asserted-by":"publisher","unstructured":"Teraki Y, Hotta T, Shiohara T. Increased circulating skin-homing cutaneous lymphocyte-associated antigen (CLA)+ type 2 cytokine-producing cells, and decreased CLA+ type 1 cytokine-producing cells in atopic dermatitis. Br. J. Dermatol. 2000;143:373\u201378. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03665.x.","DOI":"10.1046\/j.1365-2133.2000.03665.x"},{"key":"1352_CR62","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Halling A-S, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis: what does the evidence say? J Allergy Clin Immunol. 2023;151:1155\u201362. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.002.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR63","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","volume":"151","author":"GP Geba","year":"2023","unstructured":"Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151:756\u201366. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.026.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.anai.2021.04.036","volume":"127","author":"SJ Gabryszewski","year":"2021","unstructured":"Gabryszewski SJ, Hill DA. One march, many paths: insights into allergic march trajectories. Ann Allergy Asthma Immunol. 2021;127:293\u2013300. https:\/\/doi.org\/10.1016\/j.anai.2021.04.036.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1352_CR65","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/bjd.17766","volume":"181","author":"AD Irvine","year":"2019","unstructured":"Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner\u2019s guide. Br J Dermatol. 2019;181:895\u2013906. https:\/\/doi.org\/10.1111\/bjd.17766.","journal-title":"Br J Dermatol"},{"key":"1352_CR66","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","volume":"112","author":"JM Spergel","year":"2003","unstructured":"Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118-127.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR67","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0091-6749(98)70029-6","volume":"102","author":"TC Kotsimbos","year":"1998","unstructured":"Kotsimbos TC, Ghaffar O, Minshall EM, et al. Expression of the IL-4 receptor-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects. J Allergy Clin Immunol. 1998;102:859\u201366. https:\/\/doi.org\/10.1016\/S0091-6749(98)70029-6.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/rr40","volume":"2","author":"JW Steinke","year":"2001","unstructured":"Steinke JW, Borish L. Th2 cytokines and asthma\u2014interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2:66. https:\/\/doi.org\/10.1186\/rr40.","journal-title":"Respir Res"},{"key":"1352_CR69","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/nejmoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396. https:\/\/doi.org\/10.1056\/nejmoa1804092.","journal-title":"N Engl J Med"},{"key":"1352_CR70","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/13543784.2023.2215425","volume":"32","author":"MG Matera","year":"2023","unstructured":"Matera MG, Ora J, Calzetta L, et al. Investigational anti IL-13 asthma treatments: a 2023 update. Expert Opin Investig Drugs. 2023;32:373\u201386. https:\/\/doi.org\/10.1080\/13543784.2023.2215425.","journal-title":"Expert Opin Investig Drugs"},{"key":"1352_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.819772","author":"SM Nur Husna","year":"2022","unstructured":"Nur Husna SM, Md Shukri N, Tuan Sharif SE, et al. IL-4\/IL-13 axis in allergic rhinitis: elevated serum cytokines levels and inverse association with tight junction molecules expression. Front Mol Biosci. 2022. https:\/\/doi.org\/10.3389\/fmolb.2022.819772.","journal-title":"Front Mol Biosci"},{"key":"1352_CR72","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/all.15653","volume":"78","author":"NJ Campion","year":"2023","unstructured":"Campion NJ, Doralt A, Lupinek C, et al. Dupilumab reduces symptom burden in allergic rhinitis and suppresses allergen-specific IgE production. Allergy. 2023;78:1687\u201391. https:\/\/doi.org\/10.1111\/all.15653.","journal-title":"Allergy"},{"key":"1352_CR73","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/jdv.18919","volume":"37","author":"MO Christensen","year":"2023","unstructured":"Christensen MO, Barakji YA, Loft N, et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023;37:984\u20131003. https:\/\/doi.org\/10.1111\/jdv.18919.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1352_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12381","author":"LP Van Der Rijst","year":"2024","unstructured":"Van Der Rijst LP, Hilbrands MS, Zuithoff NPA, et al. Dupilumab induces a significant decrease of food specific immunoglobulin\u00a0E levels in pediatric atopic dermatitis patients. Clin Transl Allergy. 2024. https:\/\/doi.org\/10.1002\/clt2.12381.","journal-title":"Clin Transl Allergy"},{"key":"1352_CR75","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1159\/000430259","volume":"36","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Dhanapala P, Suphioglu C. Identification and characterization of a novel IL-4 receptor \u03b1 chain (IL-4R\u03b1) antagonist to inhibit IL-4 signalling. Cell Physiol Biochem. 2015;36:831\u201342. https:\/\/doi.org\/10.1159\/000430259.","journal-title":"Cell Physiol Biochem"},{"key":"1352_CR76","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/eji.1830210606","volume":"21","author":"P Garrone","year":"1991","unstructured":"Garrone P, Djossou O, Galizzi JP, et al. A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes. Eur J Immunol. 1991;21:1365\u20139. https:\/\/doi.org\/10.1002\/eji.1830210606.","journal-title":"Eur J Immunol"},{"key":"1352_CR77","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.4049\/jimmunol.144.8.3028","volume":"144","author":"CR Maliszewski","year":"1990","unstructured":"Maliszewski CR, Sato TA, Vanden Bos T, et al. Cytokine receptors and B\u00a0cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B\u00a0cell activities in vitro. J Immunol. 1990;144:3028\u201333. https:\/\/doi.org\/10.4049\/jimmunol.144.8.3028.","journal-title":"J Immunol"},{"key":"1352_CR78","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.166.9.5792","volume":"166","author":"A Tomkinson","year":"2001","unstructured":"Tomkinson A, Duez C, Cieslewicz G, et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol. 2001;166:5792\u2013800. https:\/\/doi.org\/10.4049\/jimmunol.166.9.5792.","journal-title":"J Immunol"},{"key":"1352_CR79","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.4049\/jimmunol.150.7.2717","volume":"150","author":"TA Sato","year":"1993","unstructured":"Sato TA, Widmer MB, Finkelman FD, et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol. 1993;150:2717\u201323. https:\/\/doi.org\/10.4049\/jimmunol.150.7.2717.","journal-title":"J Immunol"},{"key":"1352_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pupt.2017.01.006","volume":"43","author":"Y Liu","year":"2017","unstructured":"Liu Y, Zhang H, Ni R, et al. IL-4R suppresses airway inflammation in bronchial asthma by inhibiting the IL-4\/STAT6 pathway. Pulm Pharmacol Ther. 2017;43:32\u20138. https:\/\/doi.org\/10.1016\/j.pupt.2017.01.006.","journal-title":"Pulm Pharmacol Ther"},{"key":"1352_CR81","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/biomedicines12081841","volume":"12","author":"M Shergill","year":"2024","unstructured":"Shergill M, Bajwa B, Yilmaz O, et al. Biologic and small molecule therapy in atopic dermatitis. Biomedicines. 2024;12:1841. https:\/\/doi.org\/10.3390\/biomedicines12081841.","journal-title":"Biomedicines"},{"key":"1352_CR82","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s40267-024-01075-8","volume":"40","author":"H Shah","year":"2024","unstructured":"Shah H, Eckembrecher FJ, Eckembrecher DG, et al. Current and emerging immunobiologic therapies for atopic dermatitis. Drugs Ther Perspect. 2024;40:226\u201337. https:\/\/doi.org\/10.1007\/s40267-024-01075-8.","journal-title":"Drugs Ther Perspect"},{"key":"1352_CR83","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","volume":"48","author":"JM Alvarenga","year":"2024","unstructured":"Alvarenga JM, Bieber T, Torres T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs. 2024;48:1379\u201394. https:\/\/doi.org\/10.1007\/s40265-024-02095-4.","journal-title":"Drugs"},{"key":"1352_CR84","doi-asserted-by":"publisher","first-page":"adv00764","DOI":"10.2340\/actadv.v102.2075","volume":"102","author":"FB Sedeh","year":"2022","unstructured":"Sedeh FB, Henning MAS, Jemec GBE, et al. Comparative efficacy and safety of monoclonal antibodies and janus kinase inhibitors in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Acta Dermato-Venereol. 2022;102:adv00764. https:\/\/doi.org\/10.2340\/actadv.v102.2075.","journal-title":"Acta Dermato-Venereol"},{"key":"1352_CR85","doi-asserted-by":"publisher","first-page":"108","DOI":"10.18553\/jmcp.2022.28.1.108","volume":"28","author":"F Agboola","year":"2022","unstructured":"Agboola F, Atlas SJ, Brouwer E, et al. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value. J Manag Care Spec Pharm. 2022;28:108\u201314. https:\/\/doi.org\/10.18553\/jmcp.2022.28.1.108.","journal-title":"J Manag Care Spec Pharm"},{"key":"1352_CR86","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis. JAMA Dermatol. 2020;156:863. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406.","journal-title":"JAMA Dermatol"},{"key":"1352_CR87","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"15","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;15:2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"key":"1352_CR88","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase\u00a02b trial. Lancet. 2016;387:40\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(15)00388-8.","journal-title":"Lancet"},{"key":"1352_CR89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR90","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","volume":"140","author":"Y Han","year":"2017","unstructured":"Han Y, Chen Y, Liu X, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017;140:888\u201391. https:\/\/doi.org\/10.1016\/j.jaci.2017.04.015.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR91","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/12034754221130969","volume":"26","author":"F Koskeridis","year":"2022","unstructured":"Koskeridis F, Evangelou E, Ntzani EE, et al. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis. J Cutan Med Surg. 2022;26:613\u201321. https:\/\/doi.org\/10.1177\/12034754221130969.","journal-title":"J Cutan Med Surg"},{"key":"1352_CR92","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","volume":"184","author":"MJ Cork","year":"2021","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged \u2265 6 to < 12\u00a0years with uncontrolled severe atopic dermatitis: results from an open-label phase\u00a0IIa study and subsequent phase\u00a0III open-label extension study. Br J Dermatol. 2021;184:857\u201370. https:\/\/doi.org\/10.1111\/bjd.19460.","journal-title":"Br J Dermatol"},{"key":"1352_CR93","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/s0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6\u00a0months to younger than 6\u00a0years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2022;400:908\u201319. https:\/\/doi.org\/10.1016\/s0140-6736(22)01539-2.","journal-title":"Lancet"},{"key":"1352_CR94","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u00a0years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase\u00a03 trial. J Am Acad Dermatol. 2020;83:1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054.","journal-title":"J Am Acad Dermatol"},{"key":"1352_CR95","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/cts.13656","volume":"16","author":"J Wang","year":"2023","unstructured":"Wang J, White J, Sansone KJ, et al. Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4R\u03b1: two phase\u00a0I randomized trials, in healthy individuals and patients with atopic dermatitis. Clin Transl Sci. 2023;16:2614\u201327. https:\/\/doi.org\/10.1111\/cts.13656.","journal-title":"Clin Transl Sci"},{"key":"1352_CR96","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","volume":"153","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Strober B, Feinstein B, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: a phase\u00a02 randomized trial (CBP-201-WW001). J Allergy Clin Immunol. 2024;153:1040-1049.e1012. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.924.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR97","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s13555-023-01010-1","volume":"13","author":"CJ Wynne","year":"2023","unstructured":"Wynne CJ, Cole A, Lemech C, et al. Safety, pharmacokinetics and preliminary efficacy of IL4-R\u03b1 monoclonal antibody AK120 in both healthy and atopic dermatitis subjects: a phase I, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human clinical study. Dermatol Ther. 2023;13:2357\u201373. https:\/\/doi.org\/10.1007\/s13555-023-01010-1.","journal-title":"Dermatol Ther"},{"key":"1352_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109677","volume":"253","author":"F Cevikbas","year":"2023","unstructured":"Cevikbas F, Ward A, Firth C, et al. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clin Immunol. 2023;253:109677. https:\/\/doi.org\/10.1016\/j.clim.2023.109677.","journal-title":"Clin Immunol"},{"key":"1352_CR99","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/nejmoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase\u00a03 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080\u201391. https:\/\/doi.org\/10.1056\/nejmoa2206714.","journal-title":"N Engl J Med"},{"key":"1352_CR100","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13555-023-01058-z","volume":"14","author":"K Rand","year":"2024","unstructured":"Rand K, Ramos-Go\u00f1i JM, Akmaz B, et al. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther. 2024;14:169\u201382. https:\/\/doi.org\/10.1007\/s13555-023-01058-z.","journal-title":"Dermatol Ther"},{"key":"1352_CR101","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase\u00a0III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437\u201349. https:\/\/doi.org\/10.1111\/bjd.19574.","journal-title":"Br J Dermatol"},{"key":"1352_CR102","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2304027","author":"F Martora","year":"2024","unstructured":"Martora F, Patruno C, D\u2019Ascenzo S, et al. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. J Dermatol Treat. 2024. https:\/\/doi.org\/10.1080\/09546634.2024.2304027.","journal-title":"J Dermatol Treat"},{"key":"1352_CR103","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.jaci.2017.04.004","volume":"139","author":"T Czarnowicki","year":"2017","unstructured":"Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139:1723\u201334. https:\/\/doi.org\/10.1016\/j.jaci.2017.04.004.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Prim. 2018;4:1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Nat Rev Dis Prim"},{"key":"1352_CR105","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2024.05.029","volume":"91","author":"T-L Lin","year":"2024","unstructured":"Lin T-L, Fan Y-H, Fan K-S, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population-based cohort study. J Am Acad Dermatol. 2024;91:466\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.029.","journal-title":"J Am Acad Dermatol"},{"key":"1352_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1293185","author":"A De Greef","year":"2023","unstructured":"De Greef A, De Montjoye L, Bieber T, et al. Atopic dermatitis: a need to define the disease activity. Front Med. 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1293185.","journal-title":"Front Med"},{"key":"1352_CR107","doi-asserted-by":"publisher","first-page":"adv00731","DOI":"10.2340\/actadv.v102.295","volume":"102","author":"S Miyamoto","year":"2022","unstructured":"Miyamoto S, Imai Y, Natsuaki M, et al. Long-term remission of atopic dermatitis after discontinuation of dupilumab. Acta Dermato-Venereol. 2022;102:adv00731. https:\/\/doi.org\/10.2340\/actadv.v102.295.","journal-title":"Acta Dermato-Venereol"},{"key":"1352_CR108","unstructured":"Paller AS SE, Bieber T, et al. New hope for pediatric atopic dermatitis: preliminary data on therapy-free remission with dupilumab. In: 2024 Society for pediatric dermatology annual meeting, Toronto, ON, 2024."},{"key":"1352_CR109","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","volume":"91","author":"J Zhang","year":"2024","unstructured":"Zhang J, Boesjes CM, Loman L, et al. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry. J Am Acad Dermatol. 2024;91:300\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.026.","journal-title":"J Am Acad Dermatol"},{"key":"1352_CR110","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2022.12.824","volume":"151","author":"T Bieber","year":"2023","unstructured":"Bieber T. In search of the Holy Grail in atopic dermatitis: will dupilumab become the first disease-modifying atopic dermatitis drug? J Allergy Clin Immunol. 2023;151:1097\u20136825. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.824.","journal-title":"J Allergy Clin Immunol"},{"key":"1352_CR111","doi-asserted-by":"publisher","first-page":"11380","DOI":"10.3390\/ijms241411380","volume":"24","author":"JG Gatmaitan","year":"2023","unstructured":"Gatmaitan JG, Lee JH. Challenges and future trends in atopic dermatitis. Int J Mol Sci. 2023;24:11380. https:\/\/doi.org\/10.3390\/ijms241411380.","journal-title":"Int J Mol Sci"},{"key":"1352_CR112","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","volume":"126","author":"N Puar","year":"2021","unstructured":"Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126:21\u201331. https:\/\/doi.org\/10.1016\/j.anai.2020.08.016.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01352-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:04:29Z","timestamp":1741939469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01352-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA and UCB. Tiago Torres is also an Editorial Board member of Dermatology and Therapy. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Pedro Mendes-Bastos has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by Lilly, AbbVie, Janssen, Novartis, LEO Pharma, Almirall, Sanofi, Regeneron, Viatris, Pierre Fabre, L\u2019Or\u00e9al, Organon, Evelo Biosciences, CS Portugal, Pfizer, Biogen, Apogee, Amgen. Margarida Gon\u00e7alo has participated in clinical trials, advisory board and\/or lectures promoted by Abbvie, Almirall, Amgen, AstraZeneca, Biogen, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi-Genzyme, Takeda. Maria Jo\u00e3o Cruz has participated in clinical trials, advisory board and\/or lectures promoted by Abbvie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Novartis, Pfizer and Sanofi-Genzyme. Bruno Duarte has participated in clinical trials, advisory board and\/or lectures promoted by Abbvie, Almirall, Janssen, Leo Pharma, Eli Lilly, Pfizer and Sanofi-Genzyme. Maria Jo\u00e3o Paiva-Lopes has participated in clinical trials, advisory board and\/or lectures promoted by AbbVie,\u00a0Almirall, Boehringer\u00a0Ingelheim, Janssen, Leo-Pharma, Eli\u00a0Lilly, Novartis, Pfizer, Sanofi-Genzyme,\u00a0Viatris. Paulo Filipe has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study did not involve new studies with human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}